| Literature DB >> 31114355 |
Koudi Bai1, Yuan Sun2, Wei Li3, Lanlan Zhang4.
Abstract
Objective: To evaluate the diagnostic performance of apparent diffusion coefficient (ADC) for local staging of prostate cancer.Entities:
Keywords: apparent diffusion coefficient; extraprostatic extension; length of capsular contact; magnetic resonance imaging; prostatic cancer
Year: 2019 PMID: 31114355 PMCID: PMC6489658 DOI: 10.2147/CMAR.S191738
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Figure 1Study selection process for this systematic review and meta-analysis.
Demographic characteristics of included studies
| First author | Year | Country | Period | Patients | Proved after RP | Age | PSA | GS (range) | Disease | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Range | Mean ± SD | Range | ||||||||
| 2015 | USA | January 2010/September 2013. | 111 | 40 | 64* | 45–75 | 8.9* | 2.5–44 | 6–9 | ECE | |
| 2015 | Denmark | September 2011/September 2013 | 87 | 31 | 66.5*† | 47–74 | 12.0*† | 4.6–45.0 | 6–10 | ECE | |
| 2018 | Colombia | May 2011/December 2013 | 79 | 31 | 61.1±7.5 | 39–78 | 7.0±7.25* | 0.02–31 | 6–10 | ECE | |
| 2015 | USA | January 2010/December 2012 | 112 | 26 | 62.8±7.5 | NR | 8.2±7.2 | NR | ≥6 | EPE | |
| 2016 | Italy | January 2012/December 2014 | 70 | 23 | 63.97 | 58.9–70.5 | 6.82 | 5–9.88 | ≥6 | EPE | |
| 2016 | Japan | April 2012/June 2014 | 43 | 18 | 69 | 54–84 | 7.57 | 1.2–30 | 6–9 | EPE | |
| 2017 | Japan | August 2007/March 2015 | 210 | 56 | 67 | 50–81 | 7.0 | 2.9–30.0 | 5–10 | ECE | |
| 2015 | Korea | January 2012/December 2012 | 117 | 50 | 68.0±6.8 | 48–83 | 12.24 | 0.84–81.20 | 6–10 | ECE | |
| 2016 | Korea | January 2012/December 2012 | 185 | 51 | 66.7±7.0 | 45–79 | 10.2±13.6 | 0.5–123 | 6–9 | ECE | |
| 2015 | Canada | April 2012/June 2014 | 65 | 42 | 62.8±6.0 | NR | 9.0±8.6 | NR | 6–10 | EPE | |
| 2017 | Sweden | June 2014/January 2015 | 94 | 39 | 65.1* | 51.0–76.5 | 5.9* | 1.8–49.0 | NR | EPE | |
| 2016 | USA | May 2007/December 2015 | 379 | 87 | 61.0* | 47–75 | 8.8* | 0.2–53.5 | ≥6 | EPE | |
| 2015 | Netherlands | January 2010/May 2013 | 133 | 60 | 61 | 47–72 | 8.6* | 2.5–76.0 | 5–10 | EPE | |
| 2015 | USA | NR | 180 | 46 | 64±8 | NR | 9.0±11.4 | NR | 6–9 | EPE | |
| 2016 | Canada | January 2012/June 2014 | 113 | 76 | 61.9±5.4 | NR | 10.7±10.6 | NR | 6–9 | EPE | |
| 2018 | Norway | December 2009/June 2012 | 183 | 103 | 65* | 60–68 | 7.9* | 5.8–11.5 | 6–9 | EPE | |
| 2017 | Canada | November 2012/May 2015 | 149 | 92 | 62.3±6.3 | NR | 6.33±3.29 | NR | 6–9 | EPE | |
| 2015 | Canada | May 2012/May 2015 | 73 | 38 | 62.8±5.7 | NR | 10.7±10.6 | NR | 6–9 | EPE | |
Notes: *Median, †only for proved.
Abbreviations: ECE, extracapsular extension; EPE, extraprostatic extension; GS, Gleason score; PSA, prostate-specific antigen; RP, radical prostatectomy; NR, not reported.
Clinical and technical characteristics of included studies
| Study | Clinical | Assessment | Technical | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Design | Reference | Analysis | Readers | Experience (Year) | Blinding | Field Strength | Coil | Protocols | Cutoff | |||
| Retrospective | RP | Patient | 1 | ≥800 cases | NR | LCC | 1.5T | Body | T2/DWI | 20 | 50/1000 | |
| Prospective | RP | Patient | 2 | ≥2 | Blind* | PI-RADS† | 3T | PPA | T2/DWI/DCE | 4 | 100/800 | |
| Retrospective | RP | Patient | 2 | 8/14 | Blind* | LCC | 1.5T | None | T2/DWI/DCE | 12 | NR | |
| Retrospective | RP | Patient | 1 | NR | NR | PI-RADS† | 3T | PPA | T1/T2/DWI/DCE | 3 | 400/800 | |
| Retrospective | RP | Patient | 2 | NR | Blind | ADC values | 1.5T | ERC | T2/DWI/DCEa | 0.84 | 0/800/1600 | |
| Retrospective | RP | Patient | 2 | 2/16 | Blind* | ADC values | 3T | PPA | T1/T2/DWI/DCE | 0.72 | 0/2000 | |
| Retrospective | RP | Patient | 2 | 5/10 | Blind | LCC | 1.5T | ERC+PPA | T2/DWI/DCE | 10 | 0/1000/2000 | |
| Retrospective | RP | Patient | 2 | 9/21 | Blind* | ADC values | 3T | None | T1/T2/DWI/DCE | 0.893 | 0/1000 | |
| Retrospective | RP | Patient | 1 | 22 | Blind | LCC | 3T | None | T1/T2/DWI/DCE | 14 | 0/1000 | |
| Retrospective | RP | Patient | 7 | 5/2–13 | NR | PI-RADS | 3T | None | T2/DWI/DCE | 3 | 0/500/1000 | |
| Retrospective | RP | Patient | 2 | ≥20 | Blind* | PI-RADS | 3T | PPA | T1/T2/DWI | 4 | 1500 | |
| Prospective | RP | Patient | 2 | 8/16 | NR | LCC | 3T | ERC | T1/T2/DWI | 12.5 | NR | |
| Retrospective | RP | Lesion | 1 | ≥20 | Blind* | PI-RADS† | 3T | ERC+PPA | T2/DWI/DCE | 13 | 100/400/800 | |
| Retrospective | RP | Lesion | 2 | 1/4 | Blind | LCC | 3T | PPA | T2/DWI/DCEa | 6 | 50/1000 | |
| Retrospective | RP | Lesion | 2 | 11/15 | Blind | LCC | 3T | None | T2/DWI/DCE | 15 | 0/500/1000 | |
| Prospective | RP | Lesion | 1 | 2 | NR | ADC values | 1.5T | Body | T2/DWI | 0.89 | 50/1000 | |
| Retrospective | RP | Patient | 2 | 11/15 | Blind | LCC | 3T | Pelvic | T2/DWI/DCE | 11 | 0/500/1000 | |
| Retrospective | RP | Patient | 2 | 9/14 | Blind | Volume | 3T | Pelvic | T2/DWI/DCE | 2.1 | 0/500/1000 | |
Notes: *These studies were blinded to pathological findings but patients’ information was partly known. †PI-RADS version 1.
Abbreviations: RP, radical prostatectomy; ADC, apparent diffusion coefficient; DCE, dynamic contrast-enhanced magnetic resonance imaging; DWI, diffusion-weighted imaging; NR, not reported; LCC, length of capsular contact; PI-RADS, Prostate Imaging Reporting and Data System; PPA, pelvic phased array; ERC, endorectal coil.
Figure 2Risk of bias and applicability concerns: review of author judgments about each domain presented as percentages for the studies included using QUADAS-2.
Figure 3Coupled forest plots of pooled sensitivity and specificity. Numbers are pooled estimates with 95% CI in parentheses. Corresponding heterogeneity statistics are provided at bottom right corners. Horizontal lines indicate 95% CIs.
Figure 4Hierarchic summary ROC plots with summary point and 95% CI areas for the overall stage of T3 detection.
Abbreviation: ROC, receiver operating characteristic.
Subgroup analysis and meta-regression
| Covariant | Sensitivity (95% CI) | Specificity (95% CI) | |||
|---|---|---|---|---|---|
| 82.62%/76.24–87.57% | 0.64 | 68.02%/56.38–77.78% | 0.89 | ||
| 80.76%/75.22–85.31% | 68.99%/59.91–76.81% | ||||
| None | 80.39%/69.04–88.28% | 0.78 | 62.69%/51.13–72.95% | 0.23 | |
| Any | 81.86%/77.82–85.30% | 71.01%/62.32–78.39% | |||
| Patient | 81.9%/77.48–85.62% | 0.74 | 68.92%/59.06–77.32% | 0.95 | |
| Lesion | 80.27%//71.61––86.78% | 69.34%/60.99–76.58% | |||
| ECE | 81.43%/74.5–86.81% | 0.94 | 70.37%/62.05–77.54% | 0.65 | |
| EPE | 81.15%/75.73–85.58% | 67.18%/55.26–77.24% | |||
| ADC | 81.41%/73.47–87.39% | 0.95 | 70.69%/59.81–79.63% | 0.54 | |
| LCC | 81.13%/76.04–85.35% | 66.59%/57.59–74.51% | |||
| - | 81.43%/77.44–84.86% | - | 68.68%/61.69–74.91% | - | |
Abbreviations: ADC, apparent diffusion coefficient; CI, confidence interval; LCC, length of capsular contact; ECE, extracapsular extension; EPE, extraprostatic extension.
Figure 5Deeks’ funnel plot, a P-value of 0.37 suggests that the likelihood of publication bias is low.